Search

Displaying results 4331 - 4340 of 5449 in total
  1. Drug

    Pleconaril

    go.drugbank.com/drugs/DB05105
    Investigational

    It acts by inhibiting viral replication. The use of pleconaril has not gained approval by the U.S. … Food and Drug Administration (FDA) due to the fact that it has been found to induce CYP3A enzyme activity, therefore increasing the risk for serious drug interactions.

  2. Drug

    Phenaridine

    go.drugbank.com/drugs/DB09178
    ExperimentalIllicit

    It was developed in 1972, and is used for surgical anasthesia in Russia. Phenaridine has similar effects to fentanyl. In rat studies, it was less potent than fentanyl.

  3. Drug

    AI-850

    go.drugbank.com/drugs/DB05842
    Experimental

    AI-850 is a Cremophor(R)-free formulation of paclitaxel, the active ingredient in Taxol(R), a product used to treat a variety of solid tumors.

  4. Drug

    Ezurpimtrostat

    go.drugbank.com/drugs/DB16458
    Investigational

  5. Drug

    Stannsoporfin

    go.drugbank.com/drugs/DB04912
    Investigational

    Stannsoporfin is a competitive heme oxygenase (HO) inhibitor being developed by InfaCare, a subsidiary of WellSpring Pharmaceuticals, for the prevention of hyperbilirubinemia in infants at risk of developing

  6. Drug

    CG7870

    go.drugbank.com/drugs/DB04981
    Investigational

    It is a replication-selective, prostate-specific antigen-targeted oncolytic adenovirus, for the treatment of hormone-refractory, metastatic prostate cancer.

  7. Drug

    MLN-977

    go.drugbank.com/drugs/DB05431
    Experimental

    It is developed by PharmaEngine to treat asthma and chronic obstructive pulmonary disease.

  8. Drug

    Mito-4509

    go.drugbank.com/drugs/DB05846
    Experimental

    It is used to treat Parkinson's Disease, Alzheimer's Disease, Retinal Disorders and other neurologic Disorders.

  9. Drug

    Tulathromycin A

    go.drugbank.com/drugs/DB11474
    ExperimentalVet approved

    It is marketed by Pfizer Inc. under the tradename Draxxin.

  10. Drug

    CDX-6512

    go.drugbank.com/drugs/DB17841
    Experimental

    Developed by Codexis, it is being investigated for the treatment of homocystinuria And Maple Syrup Urine Disease.[L46651, L46656]